MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Neoplasms
Breast Cancer, Metastatic
Interventions
Drug: Sagopilone (BAY86-5302, ZK 219477)
First Posted Date
2006-02-07
Last Posted Date
2014-12-02
Lead Sponsor
Bayer
Target Recruit Count
82
Registration Number
NCT00288249

Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa

Phase 3
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Placebo
Drug: Diane
Drug: Valette
First Posted Date
2006-01-23
Last Posted Date
2023-06-06
Lead Sponsor
Bayer
Target Recruit Count
1326
Registration Number
NCT00280657

Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles

Phase 3
Completed
Conditions
Contraception
Interventions
Drug: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)
Drug: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)
Drug: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)
First Posted Date
2005-12-15
Last Posted Date
2014-11-02
Lead Sponsor
Bayer
Target Recruit Count
1166
Registration Number
NCT00266032

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006)
First Posted Date
2005-11-29
Last Posted Date
2014-11-13
Lead Sponsor
Bayer
Target Recruit Count
53
Registration Number
NCT00259129

Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

Completed
Conditions
Hypertension, Pulmonary
Interventions
Drug: Iloprost (Ventavis, BAYQ6256)
First Posted Date
2005-11-08
Last Posted Date
2015-02-02
Lead Sponsor
Bayer
Target Recruit Count
106
Registration Number
NCT00250640

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Neoplasms
Interventions
Drug: Sagopilone (BAY86-5302 , ZK219477)
First Posted Date
2005-10-30
Last Posted Date
2015-12-31
Lead Sponsor
Bayer
Target Recruit Count
63
Registration Number
NCT00246688

Ultravist: Safety and Efficacy in Computed Tomography of Head and Body

Phase 3
Completed
Conditions
Computed Tomography
Diagnostic Imaging
Interventions
Drug: Iopromide 370 mg I/mL
Drug: Iopromide 300 mg I/mL
First Posted Date
2005-10-26
Last Posted Date
2014-02-28
Lead Sponsor
Bayer
Target Recruit Count
435
Registration Number
NCT00244140

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Phase 2
Completed
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Drug: Interferon beta 1b (Betaseron, BAY86-5046)
First Posted Date
2005-10-12
Last Posted Date
2014-05-08
Lead Sponsor
Bayer
Target Recruit Count
63
Registration Number
NCT00235989

Safety and Efficacy of SH T00660AA in Treatment of Endometriosis

Phase 3
Completed
Conditions
Endometriosis
Interventions
Drug: Visanne (SH T00660AA , BAY86-5258)
First Posted Date
2005-09-23
Last Posted Date
2014-01-09
Lead Sponsor
Bayer
Target Recruit Count
168
Registration Number
NCT00225186

Efficacy and Safety of SH T00660AA in Treatment of Endometriosis

Phase 3
Completed
Conditions
Endometriosis
Interventions
Drug: Visanne (BAY86-5258, SH T00660AA)
Drug: Placebo
First Posted Date
2005-09-23
Last Posted Date
2010-04-23
Lead Sponsor
Bayer
Target Recruit Count
198
Registration Number
NCT00225199
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy